CH
CHMMF.US Chimeric Therapeutics Limited
- Market cap
- USD 14.7M
- P/E
- -
- P/B
- 0.54x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is CHMMF.US undervalued?
Graham numberThe Graham number of Chimeric Therapeutics Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Chimeric Therapeutics Limited fundamental analysis
No fundamental analysis for Chimeric Therapeutics Limited yet.
Chimeric Therapeutics Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Chimeric Therapeutics Limited
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MM…
Full company profileChimeric Therapeutics Limited financial statements
Chimeric Therapeutics Limited annual financial statements
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | 2.65K | 2.62M | 4.51M | - | 3.97M | - |
| Gross Profit | - | -847K | 1.67M | 4.51M | -3.92K | 3.12M | - |
| Operating Income | -64.0K | -15.1M | -15.1M | -25.1M | -20.7M | -15.1M | -8.34M |
| EBITDA | 154K | -14.3M | -13.6M | -24.0M | -11.2M | -9.08M | -8.34M |
| Net Income | -64.0K | -15.1M | -15.9M | -25.5M | -12.5M | -10.4M | -18.8M |
| EPS | -0.02 | -4.64 | -4.42 | -5.89 | -1.80 | -0.77 | -0.61 |
| Balance Sheet | |||||||
| Total Assets | 100.00 | 36.5M | 34.9M | 22.4M | 15.3M | 21.6M | 1.28M |
| Total Liabilities | 64.0K | 11.4M | 9.17M | 16.7M | 12.8M | 19.6M | 8.99M |
| Shareholders' Equity | -63.9K | 25.1M | 25.7M | 5.66M | 2.47M | 1.97M | -7.71M |
| Cash & Short-term Investments | 100.00 | 22.4M | 18.4M | 2.36M | 3.05M | 5.76M | 799K |
| Total Debt | 34.0K | - | - | - | 3.59M | - | 679K |
| Cash Flow | |||||||
| Operating Cash Flow | -34.0K | -8.84M | -13.2M | -16.3M | -7.54M | -7.28M | -10.8M |
| Capital Expenditure | 16.3K | 5.31M | 538K | 112K | 0.00 | 0.00 | 10.8M |
| Free Cash Flow | -34.0K | -14.1M | -13.7M | -16.4M | -7.54M | -7.28M | - |
| Ratios | |||||||
| ROE | - | -60.1% | -61.8% | -450.5% | -507.3% | -528.3% | - |
| ROA | -64,007.0% | -41.4% | -45.6% | -114.0% | -82.0% | -48.4% | -1,470.9% |
| Net Profit Margin | - | -571,190.9% | -607.5% | -566.0% | - | -262.8% | - |
| Debt to Equity | - | - | - | - | 1.46x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Chimeric Therapeutics Limited dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 4.05M | 1.12 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:100 on Apr 22, 2026.
Who owns Chimeric Therapeutics Limited
- Insiders 15.01%
- Institutions 1.18%
- Public & others 83.81%
- Shares outstanding 147M
- Free float 44.9M
Chimeric Therapeutics Limited company profile
- Company name
- Chimeric Therapeutics Limited
- Ticker
- CHMMF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- 62 Lygon Street, Carlton, VIC, Australia, 3053
- Phone
- 61 3 9824 5254
- Website
- chimerictherapeutics.com
About Chimeric Therapeutics Limited
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors. It also develops CHM CORE-NK for the treatment of acute myeloid leukaemia/colorectal cancer, acute myeloid cancer, blood cancer, solid tumors, MMP2 expressing solid tumors, and CDH17 expressing solid tumors. The company was incorporated in 2020 and is based in Carlton, Australia.
Chimeric Therapeutics Limited management
5- Dr. Rebecca McQualterCEO, MD & Director
- Mr. Aaron LauritaChief Financial Officer
- Dr. Stephanie H. Astrow MBA, Ph.D.Chief Scientific Officer · born 1962
- Dr. Agathe BourgogneHead of Manufacturing
- Mr. Nathan Jong C.A.Joint Company Secretary